The Global Health Body Raises Alert Over Acute Shortage of Obesity Jabs
Fewer than 10% of people who could benefit from GLP-1 drugs like Wegovy are able to get them, caution the World Health Organization as it releases its first recommendations on the therapies.
With more than one billion people worldwide now obese, it is urging increased and just availability to GLP-1 medication.
According to forecasts, more than two billion are projected to be obese by 2030 unless action is taken.
"The latest guidance acknowledges that excess weight is a long-term condition that can be managed with thorough and lifelong care," stated the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and supply-chain constraints are key obstacles to broad availability to the jabs that can help people shift significant body mass, says the agency.
Skinny Jab Scarcity
Despite the current most favorable outlook, the manufacturing of GLP-1 therapies would only suffice for around 100 million people – under 10% of those who need them, per the health organization.
The advice urges governments and firms to expand access, by measures including licensing agreements.
The intellectual property rights on a key compound – the primary component of Novo Nordisk's Wegovy – is scheduled to end in a number of nations in 2026.
The Way Obesity Injections Work
GLP-1 drugs imitate a body's own hormone to slow digestion, reduce hunger and increase feelings of fullness so people reduce food intake.
Individuals usually start to lose weight in the initial weeks of beginning the once-weekly jabs.
Studies indicates people may see weight return within a year of discontinuing the treatment, as their normal hunger return.
To be above a healthy weight increases your likelihood for contracting medical conditions, including type 2 diabetes, cardiovascular issues, stroke, and specific cancers.
Excess weight impacts individuals in countries worldwide and was responsible for 3.7 million deaths worldwide in 2024, per the health agency.
